These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 8348749)

  • 41. Endogenous interferon alpha/beta produced by Kupffer cells inhibits interleukin-1, tumor necrosis factor alpha production and interleukin-2-induced activation of nonparenchymal liver cells.
    Tzung SP; Cohen SA
    Cancer Immunol Immunother; 1991; 34(3):150-6. PubMed ID: 1756531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Membrane-associated lymphotoxin-expressing lymphokine-activated killer cells up-regulate intercellular adhesion molecule-1 expression on target tumor cells in vitro.
    Kimura K; Abe Y; Horiuchi A; Miyake M; Kimura S
    Cell Immunol; 1995 Aug; 164(1):119-25. PubMed ID: 7634343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
    Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
    J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.
    Kaufmann Y; Davidsohn J; Levanon M; Icekson I; Revel M; Ramot B
    Clin Immunol Immunopathol; 1991 Feb; 58(2):278-88. PubMed ID: 1898716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients.
    Logan TF; Gooding WE; Whiteside TL; Ernstoff MS; Kaplan SS; Miketic L; Vlock DR; Tompkins C; Wood DL; Nadler PI; Kirkwood JM
    J Immunother; 1997 Sep; 20(5):387-98. PubMed ID: 9336746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.
    Limb GA; Meager A; Woolley J; Wadhwa M; Biggerstaff J; Brown KA; Wolstencroft RA
    Immunology; 1989 Dec; 68(4):514-9. PubMed ID: 2514140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
    Furbert-Harris PM; Evans CH
    Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells.
    Kondo S; Miyatake S; Kikuchi H; Oda Y; Iwasaki K; Ohyama K; Namba Y
    Neurosurgery; 1992 Sep; 31(3):534-40. PubMed ID: 1407434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells.
    Leung KH
    Cancer Immunol Immunother; 1991; 34(1):31-6. PubMed ID: 1760808
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor/lymphotoxin release by IL-1 beta, IL-4, and IL-6 in vitro.
    Dett CA; Gatanaga M; Ininns EK; Cappuccini F; Yamamoto RS; Granger GA; Gatanaga T
    J Immunol; 1991 Mar; 146(5):1522-6. PubMed ID: 1847164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
    Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
    Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.
    Koberda J; Bergmann L; Mitrou PS; Hoelzer D
    J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of lymphokine-activated killer cells from nude mouse spleen cells by interleukin-4.
    Tunru IS; Suzuki H; Kobayashi M
    Experientia; 1993 Jan; 49(1):76-9. PubMed ID: 7679079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancement of in vitro prostaglandin E2 production by mouse fibrosarcoma cells after co-culture with various anti-tumour effector cells.
    Okada F; Hosokawa M; Hasegawa J; Kuramitsu Y; Nakai K; Yuan L; Lao H; Kobayashi H; Takeichi N
    Br J Cancer; 1994 Aug; 70(2):233-8. PubMed ID: 8054271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis.
    Bo X; Broome U; Remberger M; Sumitran-Holgersson S
    Gut; 2001 Jul; 49(1):131-41. PubMed ID: 11413121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.
    Hoyer M; Meineke T; Lewis W; Zwilling B; Rinehart J
    Cancer Res; 1986 Jun; 46(6):2834-8. PubMed ID: 2421884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines.
    Bluman EM; Bartynski KJ; Avalos BR; Caligiuri MA
    J Clin Invest; 1996 Jun; 97(12):2722-7. PubMed ID: 8675682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
    Singh SM; Sone S; Inamura N; Ogura T
    Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced induction of lymphokine-activated killer activity following a single dose of cisplatin in cancer patients.
    Arinaga S; Adachi M; Karimine N; Inoue H; Asoh T; Ueo H; Akiyoshi T
    Int J Immunopharmacol; 1994 Jul; 16(7):519-24. PubMed ID: 7928001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.